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Research SR140333 counteracts NK-1 mediated cell 
proliferation in human breast cancer cell line T47D
Wei-Qing Huang1, Ji-Gang Wang2, Lei Chen3, Hong-Jun Wei1 and Hua Chen*1
Abstract
Background: It has been demonstrated that certain NK-1 antagonists could reduce proliferation of several cancer cell 
lines, however, it is unknown whether SR140333 exerts proliferation inhibition in breast cancer cell line.
Methods: Immunohistochemical staining was carried out to investigate the immunolocation of NK-1 in breast cancer 
tissues and T47D cell line, thereafter, various concentrations of [Sar9, Met(O2)11]substance P and SR140333 were 
applied alone or combined. MTT assay was applied to detect cytoactivation and coulter counter was to detect growth 
curve. The Hoechst33258 staining was performed to detect apoptosis.
Results: We found that breast cancer and T47D cells bear positive expression of NK-1. SR140333 inhibited cell growth 
in a dose dependent manner. Furthermore, SR140333 could counteract [Sar9, Met(O2)11]substance P induced 
proliferation. Hoechst33258 staining revealed the presence of apoptosis after SR140333 treatment.
Conclusions: Our study demonstrated SR140333 exert proliferation inhibition in breast cancer cell line T47D and 
indicates NK-1 play a central role in the substance P related cell proliferation in breast cancer.
Background
Breast cancer is the most common cancer among women
worldwide. It already is an urgent public health problem
in high-resource regions, and is becoming an increasingly
urgent problem in low-resource regions, where incidence
r a t e s  h a v e  b e e n  i n c r e a s i n g  b y  u p  t o  5 %  p e r  y e a r  [ 1 ] .
Despite earlier radiological examination, complete surgi-
cal resection and aggressive chemotherapy, it is still a
social dilemma. Research studies have shown relevance of
neuroendocrine molecules in breast cancer development,
such as substance P and its receptor, NK-1, which belongs
to G protein coupled receptor [2,3]. Substance P is a
member of neurokinin family. Pharmacological studies
have confirmed NK-1 as the high affinity receptor of sub-
stance P. It is well known that substance P and NK-1 are
widely expressed in neural and non-neural sources [4-11].
Moreover, substance P could mediate cell mitogenesis
through NK-1 activation [7], and using specific NK-1
antagonists (such as CP-96345, C-99994) in breast cancer
cell lines could blunt the autocrine and/or paracrine cell
proliferation [2,3].
Two forms of NK-1 are reported in humans, full-length
(NK1-FL) and truncated (NK1-Tr). The cytoplasmic end
of NK1-Tr lacks 100 residues, a region that functions as
the substrate for G protein-receptor kinase [12]. By in situ
hybridization, the existence of NK-1 mRNA has been
demonstrated in malignant breast tissue but not detected
in benign tissue [2]. Western blots showed coexpression
of NK1-Tr and NK1-FL in several different breast cancer
cell lines, including T47D [3]. Moreover, Previous RT-
PCR study showed T47D cells contain more abundant
NK-1 and substance P than others [3]. Both NK1-Tr and
NK1-FL can activate PKC through incorporating G pro-
teins, which has been suggested as a potential cancer tar-
get [13,14]. Recently, the expression of NK-1 in human
tumors has been investigated using immunohistochemis-
try [8]. In several cell types, tumor cells bear more NK-1
than normal cells. These findings suggest that NK-1 may
serve as a specific factor involved in the development of
breast cancer. However, it is unknown the exact cellular
location of NK-1 in breast cancer cells. Although earlier
in vitro studies have demonstrated that NK-1 antagonists
could inhibit the growth of certain tumor cells in pres-
ence or absence of apoptosis [2,3,15-22], no study has
been carried out on the antitumor action of specific NK-1
antagonist SR140333 in human breast cancer. Further-
* Correspondence: chenhua62@163.com
1 Department of Pathology, Qingdao Municipal Hospital, 5 Donghai Middle 
Road, Qingdao, Shandong,  266071, China
Full list of author information is available at the end of the articleHuang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:55
http://www.jeccr.com/content/29/1/55
Page 2 of 7
more, it is also unclear whether the NK-1 specific agonist
SMSP exerts proliferation promoting action or not in
breast cancer cells.
Therefore, in this study, we first generated an immuno-
histochemical study to investigate the immunolocation of
NK-1 on breast cancer tissues and T47D cell line. Then
we examined the effect of SMSP and SR140333 on in
vitro growth of human breast cancer cell line T47D and
further detected whether the NK-1 receptor antagonist
SR140333 produce apoptosis in this cell line. Our study
may enable us to develop a potential therapeutic target
for breast cancer therapy.
Methods
Reagents, antibodies, tumor tissues and cell line
Rabbit anti-NK1 (polyclonal antibody) was purchased
from Millipore Corporation (USA). The anti-NK1 pep-
tide was against the carboxyterminal tail of the NK-1
receptor, which corresponds to amino acids 393-407 of
the NK1-FL receptor. Reagent A (Polymer enhancer),
Reagent B (polymerized horseradish peroxidase-anti
mouse/rabbit lgG), citrate buffer (pH = 6.0), normal non-
immune goat serum (10%), and DAB were purchased
from Maixin (Fuzhou, China). SMSP was obtained from
Tocris (Avonmouth, UK). SR140333 was kindly provided
by Sanofi-Aventis-Chilly-Mazarin. FBS, DMEM (high
glucose), trypsin-EDTA (0.05% trypsin 0.53 mM EDTA)
were purchased from Gibco (California, USA). MTT,
DMSO and Hoechst33258 were purchased from Sigma
(Saint Louis, USA). 25 cm2 culture flakes, 96-well culture
plates and 15 mL centrifuge tubes were purchased from
Corning (New York, USA).
All breast tissues were obtained from Qingdao Munici-
pal Hospital. The patients providing the tissues did not
receive prior treatment with anticancer agents. The study
was approved by the institutional review board of
Qingdao University. The following tumors were investi-
gated: infiltrating ductal carcinoma (n = 89), infiltrating
lobular carcinoma (n = 14). The human breast cancer cell
line T47D was purchased from Chinese Type Culture
Collection (Shanghai, China). The T47D cells were
seeded in 25 cm2 culture flakes and maintained with
DMEM supplemented with 10% FBS. The medium was
renewed every two days and the cells were passaged by
treatment with trypsin-EDTA on the six day after seed-
ing. On the third day T47D cells entered exponential
phase. Cells were incubated at 37°C in CO2 incubator
(SHEL LAB, Oregon, USA) containing 5% CO2. All T47D
cells were dissociated by treatment with trypsin-EDTA at
80-90% cell confluence and inoculated at a density of
105cells/mL in 6-well plates which contained cover slips.
The medium was renewed after two days and the cover
slips were extracted on the fourth day, then the speci-
mens were put into acetone (4°C) to fix for 15 minutes.
Immunohistochemistry
All tissue specimens were fixed in formalin and embed-
ded in paraffin. Seven-μm paraffin sections were cut and
floated onto polylysine adhered slides. The sections were
dewaxed in xylene and rinsed in alcohol and graded alco-
hol/water mixtures. The immunohistochemical staning
was performed using Elivision™ plus two-step System.
Briefly, all sections were incubated with 3% hydrogen
peroxide for 15 minutes to block endogenous peroxidase
activity at first. The sections were subsequently treated in
a microwave oven twice for 6 minutes in citrate buffer at
600W to undergo antigen repairing. After blocking with
goat serum for 30 minutes, rabbit anti-human NK-1 was
applied on the sections at the dilution of 1: 700 for 90
minutes at room temperature. After rinsing, staining was
performed with Reagent A and Reagent B subsequently.
The color was developed by reacting with DAB. Sections
were then counterstained with hematoxylin, dehydrated,
cleared and coverslipped. The T47D cell specimens were
also stained by the above procedures except antigen
repairing. The specificity of immunolabelling was dem-
onstrated by the absence of labelling for NK-1 receptors
when the primary antibody was omitted. The benign
breast tumors (fibroadenoma: n = 5 and adenosis: n = 6)
are used for negative control. Pancreatic adenocarcinoma
was used as positive control for the immunohistochemi-
cal study [23].
All specimens were observed by two investigators using
an Olympus BX-51 microscope (Tokyo, Japan) Only the
brown particles that were easily visible with a low power
objective was categorized positive staining.
Drug treatment
SMSP and SR140333 were dissolved in culture medium
respectively to obtain experimental concentration. Differ-
ent concentrations of SR140333 were evaluated in pre-
liminary experiment to determine the 50% inhibition
concentration (IC50) (unpublished data). In present study
we performed various concentrations of SR140333 rang-
ing from 10-9M to 10-5M to examine. In order to deter-
mine SMSP induced cell proliferation, different
concentrations of SMSP (10-10M-10-6M) were evaluated.
Furthermore, to learn whether SR140333 could counter-
act SMSP induced effect or not and at which concentra-
tion the counteract function would occur, we carried out
competition experiments in which all T47D cells were
treated using SMSP combined with various concentra-
tions of SR140333. The most effective concentration of
SMSP for this cell line was incubated 1 hour before the
addition of SR140333.Huang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:55
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Proliferation assay
Cell proliferation was assessed using MTT assay. Cells
were cultured in 96-well plates and the cell numbers were
quantified using a coulter counter (Coulter Electronics,
Inc., Hialeah, FL). Each well contained 2 × 104cells in a
total volume of 200 μL. The plate included blank wells (0
cells/mL), control wells (2 × 104cells/0.2 Ml, untreated
group), control wells with DMSO (no cells), control wells
treated with SR140333 (10-9M-10-5M), control wells
treated with SMSP (10-10M-10-6M) and control wells
treated with SMSP (most effective concentration) com-
bined with different concentrations of SR140333 (10-9M-
10-5M). Drugs were added on day 3 (at exponential phase)
and the assay was performed after 24 hours. For the pro-
liferation assay, 20 μL MTT was added in each well. After
4 hour at 37°C supernatant was removed and 100 μL
DMSO was added in each well. The optical density (OD)
was detected in the microplate reader at 570 nm wave-
length (Biotech Instruments, New York, USA). Each
experimental condition (blank wells, control wells, and
control wells treated with drugs) was assayed in duplicate
and each study was repeated on at least three separate
occasions. Representative data from each experiment are
shown in this article.
Growth study
T47D cells (2 × 105cells/mL) were grown in 24-well tissue
culture plates and each well containing 500 μL DMEM
with 10% FBS. After 24 hours, medium was removed and
fresh medium containing SMSP (the most effective con-
centration) or SR140333 (10-5M) was added at the same
time (day 1). Control cells received only DMEM con-
tained 10% FBS. On the subsequent five days, total cell
counts were performed by a Coulter counter. Cell num-
bers determined by a Coulter counter were similar (less
than 5% difference) to viable cell numbers determined by
a dye (trypan blue) exclusion method using a hemocy-
tometer.
Hoechest33258 staining
In order to determine whether apoptosis is induced by
the specific NK-1 antagonist SR140333, Hoechst33258
staining was performed. T47D cells were cultured in a 6-
well plate using the cover slip culture method. On the
third day SR140333 (10-5M) was added and 24 hours later
all the cover slips were taken out. Control cells were
treated only with culture medium. The cell samples were
washed twice with PBS and fixed by incubation with gla-
cial acetic acid/methanol mixture (glacial acetic acid:
methanol = 1:3) for 30 minutes. Following washing in
PBS, cells were incubated in 1 μg/mL Hoechst33258 solu-
tion for 10 minutes in the dark at 37°C. The cells were
analyzed by a fluorescence microscope (Olympus BX-51,
Tokyo, Japan).
Statistical analysis
Statistical analysis was performed with SPSS 10.0 statisti-
cal software for Microsoft Windows. Values of prolifera-
tion assay and growth study were expressed as means ±
SD. Data from the proliferation assay were analyzed using
one-way ANOVA. The homogeneity of the variance was
tested using the Levene test. If the variances were homo-
geneous, Fischer's least significant difference procedure
for multiple comparisons with Bonferroni adjustment
and Dunnett t tests were used. For data sets with non-
homogeneous variances, the ANOVA test with T3 Dun-
n e t t  p o s t  h o c  a n a l y s i s  w a s  a p p l i e d .  D a t a  f r o m  g r o w t h
study were analyzed using Dunnett t tests. We only con-
sidered the variances among different treating factors at
the same day. The criterion for significance was p < 0.05
for all comparisons.
Results
Expression of NK-1 in breast cancer tissues and T47D cells
Prominent NK-1 immunostaining was detected in most
malignant breast cancer tissues (infiltrating ductal carci-
noma was 78/89 and infiltrating lobular carcinoma was
12/14, respectively) and T47D cells. The positively
stained cells were widely distributed, and NK-1 receptors
were present on nearly all breast cancer cells. The brown
particles were frequently observed in plasma membrane
and/or cytoplasma (Figure 1). The benign tumor tissues
bear negative expression of NK-1.
Effects of SMSP and SR140333 on the proliferation of T47D 
cells
On the third day T47D cells entered exponential phase
and different concentrations of SMSP was added. The
results of MTT assay revealed that SMSP showed stimu-
latory effect at concentrations from 10-10M to 10-7M. Fur-
thermore, at 10-8M SMSP exhibited the most effective
stimulation manner. Instead, 10-6M of SMSP showed
inhibitory effect as compared to the untreated group (Fig-
ure 2).
Proliferation inhibition of T47D cells by SR140333 was
detected after the addition of increasing concentrations
of the specific NK-1 antagonist. SR140333 showed the
inhibitory effect in a dose dependent fashion at concen-
trations ranged from 10-8M to 10-5M, but 10-9M of
SR140333 did not inhibit cell proliferation as compared
to the untreated group (Figure 2).
As 10-8M of SMSP exhibited the most effective stimula-
tion manner, we took 10-8M as the most effective concen-
t r a t i o n  t o  i n v e s t i ga t e .  As  c o m pa r ed  wi t h  c o n t r o l s  wi t h
SMSP alone, all cells showed proliferation inhibitory
effect after administration of SMSP combined with vari-
ous concentrations of SR140333. SR140333 inhibited the
stimulatory effect of SMSP in a dose-dependent fashion.
As compared with the untreated group, at 10-6M and 10-Huang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:55
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5M SR140333 could totally block 10-8M of SMSP induced
stimulatory effect, and 10-5M of SR140333 showed inhib-
itory effect in the presence of 10-8M of SMSP. However,
low concentrations of SR140333 (10-9M, 10-8M, and 10-
7M) combined with 10-8M of SMSP still showed stimula-
tory effect. These results suggest SR140333 counteract
SMSP induced proliferation in a dose dependent manner.
Furthermore, SR140333 could block even reverse SMSP
induced cell proliferation (Figure 3).
Compared with untreated group (control), cells treated
with SMSP showed growth stimulatory effect from the
third day while SR140333 showed growth inhibitory
effect from the fourth day. In the successive five days after
the administration of SR140333, growth rates of T47D
cells were not reduced to zero, though (Figure 4).
SR140333 induces apoptosis of T47D cells
Hoechst33258 staining revealed the presence of a great
number of apoptotic cells after administration of
SR140333 (Figure 5). Typical morphological change of
apoptotic cells was easily observed, which showed char-
acteristic of chromatin condensation and nuclear frag-
mentation. In fact, we observed a 25.58 ± 3.86 (SD) % of
apoptotic cells after administration of SR140333 while
only 7.85 ± 1.53 (SD) % in the untreated cells (p < 0.01).
Figure 3 Effect of SMSP (10-8M) combined with different concen-
trations of SR140333 (10-9M-10-5M) on proliferation of T47D cell 
line. The asterisk below the bars indicates p value vs. SMSP group 
whereas that over the bars represents p value vs. untreated group. *p 
< 0.01; #no significance. Vertical bars indicate SD.
Figure 1 Expression of NK-1 in Breast cancer and T47D cells. A, 
Positive NK-1 receptor staining was present on nearly all tumor cells in 
infiltrating ductal cancer, and the plasma membranes were positively 
stained. B, Immunostaining of NK-1 receptor could also be observed in 
cytoplasma in infiltrating lobular cancer cells. C, The immunolabelling 
of NK-1 was located in membrane. Scale bars: A, C = 50 μm, B = 100 μm.
Figure 2 Effect of different concentrations of [Sar9, Met(O2)11] 
substance P (SMSP) and SR140333 on proliferation of T47D cell 
line. *p < 0.01; Δp < 0.05. Vertical bars indicate SD.Huang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:55
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Discussion
Our present study has clearly demonstrated expression of
NK-1 in breast cancer tissues and T47D cell line using
immunohistochemical study. This result is in agreement
with the previous study which demonstrated that NK-1 is
increased in breast biopsies by in situ hybridization [2].
Moreover, previous study has shown that malignant
breast tissues bear over-expression of substance P [2],
indicating involvement of neuroendocrine mechanism in
breast cancer development. NK-1 receptors in tumor
cells increase the amount of mitotic signals for the tumor
cell, counteracting the different apoptotic and/or pro-
senescent pathways activated in the neoplastic cell popu-
lation [24]. In breast cancers, increasing substance P
could enhance the message transmitting through increas-
ing NK-1; this may accelerate the proliferation process.
The increasing number of NK-1 in T47D cells leads us
to investigate the role of NK-1 in tumor cell proliferation
and growth. Therefore, we performed an in vitro study in
which NK-1 receptors were activated or blocked by spe-
cific agonist SMSP or specific antagonist SR140333. The
data of this study have shown, for the first time, that
SMSP could stimulate the proliferation of breast cancer
cell line T47D while SR140333 showed growth inhibitory
effect. Further study by MTT assay has shown that
SR140333 counteracted SMSP induced proliferation of
T47D cells in vitro. These results suggest that the down-
stream signal transduction following NK-1 activation is
significant for breast cancer development. It is known
that substance P stimulates mitogenesis by activating NK-
1 receptors in several neoplastic cell types [25,18,4-11].
Since we merely exerted SMSP not exogenous substance
P in this study, the exact effect of substance P on breast
cancer cell line is still unclear. As endogenous substance P
exhibits high affinity to NK-1 in vivo [10,11], the present
study suggests that NK-1 plays a central role in substance
P related cell proliferation in T47D cells. Thus, we con-
clude that blocking NK-1 by SR140333 also could inhibit
substance P induced cell proliferation in T47D cells. An
observation cannot be explained was 10-6M of SMSP
showed inhibitory effect, and the detail needs to be fur-
ther studied.
The other finding in this study was the presence of visi-
ble apoptosis after administration of SR140333. This is
consistent with earlier studies, in which the use of certain
NK-1 antagonists inhibited the growth of other human
breast cancer cell lines such as MDA-MB-231 and MDA-
MB-468 [26,27]. It was speculated that this finding was
induced by a signal transduction pathway for apoptosis
Figure 4 Growth curve for T47D cell line in the presence of SMSP 
(10-8M) and SR140333 (10-5M) alone (evaluation by cell counting 
method). Both reagents were added respectively when the popula-
tions adhere to the flask. At different times, T47D cells were detached 
and then counted using a coulter counter. The results are shown as 
mean ± SD of four different experiments. Data of each day was ana-
lyzed by one-way ANOVA with Dunnett t test. *p < 0.01 vs. control; #no 
significance vs. control. Vertical bars indicate SD.
Figure 5 Hoechst33258 fluorescent staining after SR140333 
treatment (A, SR140333 treated cells; B, control). T47D cells were 
cultured in DMEM contained 10%FBS and SR140333 was added at log-
arithmic growth phase (on day 3, at about 30% cell confluences). We 
carried out Hoechst33258 staining on specimens obtained by the cov-
er slip culture method. After treated with SR140333 for 24 h, T47D cells 
showed slower proliferation profile and visible apoptosis was detected 
by Hoechst33258.Huang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:55
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[7,20,28,29]. In addition, the blockade of NK-1 could
inhibit both DNA synthesis and cell proliferation by the
mitogen-activated protein kinase (MAPK) pathway [25].
However, in the presence of CP-96345 or C-99994, which
belongs to NK-1 antagonist, no apoptotic cells but only
inhibitory effect was observed in human breast cancer
cell line T47D [2,3]. The authors think the reason is that
the cell cycle remained in the G2 phase [2]. Probably this
different power action could be related with the different
affinity for the NK-1 and with the expression of the
amount of NK-1 receptors in the different tumor cells
[30]. Moreover, previous studies have demonstrated that
in the great majority of malignant tumors, NK-1 recep-
tors were found on intra- and peritumoral blood vessels
[6,23]. This finding indicated that NK-1 may serve as a
preferred target for cancer therapy, which could mediate
vasodilatation and mitogenesis. In fact, our unpublished
immunohistochemical study has demonstrated the
expression of NK-1 on both intratumoral and peritu-
moral blood vessels. Therefore, targeting NK-1 using
SR140333 could decrease both nutrition supply and sig-
nal transduction.
It is well known that cell growth is regulated by various
growth factors through their specific receptor linked var-
ious signal-transduction pathways [31]. A peptide growth
factor may act through different receptors coupled to dif-
ferent post-receptor signal-transduction pathways [32] or
the same receptor for a given peptide growth factor may
be coupled to different post-receptor signal-transduction
pathways by crosstalk [33]. T47D cells contain estrogen
receptors (ER), and the ER dimer binds either directly to
DNA at an estrogen response element or tethers to other
bound transcription factors, thereby altering the tran-
scription of estrogen sensitive genes [34] Although most
ER is in the nucleus, a population resides in the cyto-
plasm and/or membrane, available for cross talk with
other cytoplasmic/membrane-associated signaling mole-
cules, such as shc. Because ER itself has no kinase activity,
phosphorylation must occur through another molecule
that associates with ER or is activated by the receptor.
The activation of NK-1 induces releasing of G-protein βγ
subunits, and the latter recruit components of the ras-
dependent cascade, such as shc, grb2, and src, leading to
the activation of raf-1 and MAPK [35]. Shc binds to ER
and src in T47D cells, leading to estradiol-induced activa-
tion of the MAPK pathway [36]. Therefore, the estradiol-
induced nongenomic signaling pathway can also be acti-
vated by downstream of NK-1 pathway. As most ER is in
nucleus, genomic signaling pathway is more important
than nongenomic pathway. We speculate blockade of NK-
1 only cut estradiol-mediated MAPK pathway. At pres-
ent, it is still unclear whether SR140333 could counteract
estradiol induced T47D's proliferation or not. The block-
ade of NK-1 by SR140333 could only break off one of
many kinds of receptor related cell proliferation. Thus,
only slower growth rate was observed and the growth rate
was not reduced to zero (Figure 2) after administration of
antagonist SR140333.
Conclusions
W e have demonstrated the presence of NK -1 in breast
cancer using immunohistochemistry. We also demon-
strated the stimulatory effect of SMSP and inhibitory
effect of SR1403333 on human breast cell line T47D. As
only T47D cell line was bring into the present study, the
effect of SR140333 on other cell lines is still not clear. Our
observations indicate NK-1 may serve as a novel marker
and target of breast cancer to study in the future.
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